All Trials

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–2 melanoma (stage IIB–IV with progression on or within 6 months after adjuvant anti–PD-1, including select rare subtypes with metastatic immunotherapy failure) or unresectable stage II/III–IV soft tissue sarcoma with accessible measurable disease and early resistance/need to continue anti–PD-1 therapy are enrolled, requiring surgically obtainable tumor for vaccine manufacture. Patients receive an individualized autologous total tumor mRNA vaccine formulated in DOTAP lipid particles (IV 3-dose series) intended to enhance antigen presentation/innate activation and re-sensitize to checkpoint blockade, followed by continuation/resumption of anti–PD-1 per protocol.

ClinicalTrials.gov ID: NCT05264974

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

Restricted enrollment

The trial has restricted enrollment. For instance, you may only be eligible to participate if you were enrolled in a specific prior trial.

TrialFetch AI summary: This trial enrolls patients with BRAF V600E/K mutant cancers who previously received and benefited from dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), or their combination in Novartis or GSK-sponsored studies, and who lack access to commercial therapy. Patients continue their prior targeted regimen to assess long-term safety and tolerability.

ClinicalTrials.gov ID: NCT03340506